
    
      This is a phase II controlled randomized study comparing atezolizumab as single agent to the
      combination of atezolizumab and bevacizumab in patients with chemonaive metastatic NSCLC with
      PD-L1 expression.

      A total of maximum of 206 patients will be enrolled in the study. Patients will be treated
      with atezolizumab (1200 mg) every 3 weeks (6-week cycles) or the combination of atezolizumab
      (1200 mg) every 3 weeks (6-week cycles) plus bevacizumab (15 mg/kg) every 3 weeks until
      disease progression, unacceptable toxicity or patient refusal. Disease evaluation, along with
      various assessments, will be made every 3 weeks and every 6 weeks and follow-up every 3
      months. Toxicities will be evaluated throughout the study period. A follow-up of 12 months is
      planned for each patient from the end of treatment .The study will be performed in
      approximately 20 centers across Italy.
    
  